Poussot Rodolphe Jean 4

What Happened

• Rodolphe Jean Poussot, SVP — Strategy & Corporate Development at West Pharmaceutical (WST), had restricted stock units (RSUs) convert into 383.382 shares on Feb 20, 2026 (reported on Form 4 filed Feb 23, 2026). Of those shares, 129.545 were surrendered/withheld to cover tax withholding at $241.12 per share, totaling $31,236. Based on the $241.12 per-share price, the gross value of the converted shares was about $92.4K, leaving a net ~253.837 shares retained.

Key Details

• Transaction date: February 20, 2026; Form 4 filed: February 23, 2026.
• Primary actions reported:
  • M (conversion of derivative): 383.382 shares acquired (RSUs converting 1-for-1).
  • F (payment of tax liability): 129.545 shares withheld/disposed at $241.12/share for $31,236.
  • A separate reported M line lists 383.382 shares disposed at $0.00 — this represents the conversion reporting for the derivative (no cash proceeds).
• Shares owned after the transaction: not specified in the filing (net retained from this vesting ≈ 253.837 shares).
• Footnotes: F1 confirms RSUs convert one-for-one to common stock. F2 notes the RSUs were originally granted Feb 20, 2024 (1,143 RSUs vesting in three equal annual installments).

Context

• This is a routine RSU vesting with share withholding to satisfy tax obligations (common net-share settlement). It is not an open-market purchase or sale that signals a directional trade. The M code indicates conversion of a derivative (RSU → common stock); the F code indicates tax withholding.